Association between Responsiveness to Phenobarbital Induction of CYP2B1/2 and 3A1 in Rat Hepatic Hyperplastic Nodules and Their Zonal Origin

by Zhi-Ying Chen¹ and David L. Eaton¹

To explore further the mechanism underlying the alteration in expression of P450 enzymes in hepatic preneoplastic lesions, expression of CYP2B1/2 and 3A1 in individual hepatic hyperplastic nodule induced by an aflatoxin B₁ (AFB₁) administration protocol and the Solt-Farber resistance protocol in male F344 rats was examined via immunohistology. In nodules induced by the resistance protocol, expression of both CYP2B1/2 and 3A1 proteins was highly variable among different nodules, whereas these P450 proteins were expressed in all nodules induced by the AFB protocol. Nodules induced by the resistance protocol have been shown previously to arise from throughout the acinar lobule. In contrast to the resistance protocol, the AFB protocol causes extensive periportal necrosis, potentially resulting in a heavy selection pressure for clonal expansion of initiated cells arising from the centrilobular area. As phenobarbital-induced expression of both CYP2B1/2 and 3A1 in normal liver is heavily localized to the centrilobular zone, these observations suggest that the ability of preneoplastic nodules to respond to induction of these P450 proteins is determined primarily from the zonal origin of the precursor hepatocytes. Thus, the nodules from the resistance protocol that express little or no CYP2B1/2 and 3A1 may have been derived from the periportal hepatocytes, whereas all the nodules in the AFB group and some of the nodules from the resistance protocol which expressed these P450 proteins in response to phenobarbital induction may have been derived from centrilobular hepatocytes.

Introduction

Alternation in expression of cytochromes P450 in preneoplastic and neoplastic lesions is a common phenomenon during chemical hepatocarcinogenesis (1-5). There is increasing evidence to suggest that altered expression of P450 enzymes in the preneoplastic and neoplastic lesions may play a functional role in liver tumor promotion by nongenotoxic carcinogens. Numerous studies have demonstrated an association between induction of P450 enzymes and the potential for liver tumor promotion by nongenotoxic carcinogens such as barbiturates, phenytoin, and DDT (6-10). In recent years, expression of several forms of P450 proteins, e.g., CYP1A1, 1A2, 2B1/2, 2C6, 2C11, and 3A1, has been examined in individual preneoplastic and neoplastic lesions via immunohistological studies (11-17). Results of these studies suggest that individual forms of P450 protein are expressed differently in different lesions. Furthermore, some studies (13,14) have demonstrated that larger or more advanced lesions under-express P450 enzymes relative to smaller or less advanced lesions, suggesting that decreased expression of P450 enzymes may be an important factor in the growth and development of the preneoplastic lesions in the absence of exogenous promoter treatment.

Recently, a series of studies has been conducted in our laboratory to further explore the mechanism underlying the alteration of P450 enzyme expression in preneoplastic lesions in rat livers. We present here evidence to suggest that the ability of preneoplastic nodules to respond to induction of CYP2B1/2 and 3A1 by phenobarbital is determined primarily from the zonal origin of the precursor hepatocytes.

¹Department of Environmental Health, SC-34, University of Washington, Seattle, WA 98195. Address reprint requests to Z.-Y. Chen, Department of Environmental Health, SC-34, University of Washington, Seattle, WA 98195. This paper was presented at the Symposium on Cell Proliferation and Chemical Carcinogenesis that was held January 14-16, 1992, in Research Triangle Park, NC.


**Induction of Rat Hepatic Nodules**

Hepatic hyperplastic nodules were induced in male F344 rats (Simonsen Co., Gilroy, CA) either by a modified Solt-Farber resistance protocol or an aflatoxin B<sub>1</sub> (AFB) administration protocol. Details of these two protocols have been reported elsewhere (16-18). The expression pattern of GGT (gamma-glutamyltranspeptidase) was determined histochemically, and express of GST-P (glutathione S-transferase) was determined immunohistochemically, as described previously (16,17). The expression of CYP1A1, 1A2, 2B1, 2B2, 3A1, 2C6, and 2C11 in individual lesions was determined immunohistochemically, and by Northern or slot-blot analysis of mRNA preparations using specific P450 oligomers.

**Zonal Differences in Responsiveness**

A polyclonal antibody reacting to both CYP2B1 and 2B2 was used to study the expression pattern of CYP2B1/2 in rat liver via immunohistochemical staining. The proteins demonstrated by this antibody are therefore designed as CYP2B1/2 proteins. Data from these studies demonstrated that CYP2B1/2 proteins were positive only in acinar zones 2 and 3 (centrilobular) and negative in zone 1 (periportal) in normal, surrounding tissue in the livers of phenobarbital-treated rats in both AFB and Solt-Farber resistance protocol groups (Fig. 1D, 2D, and E). These data are in agreement with previous studies of the distribution of mRNA and protein of these two P450 enzymes (19-21). Using an antibody specific to CYP3A1, CYP3A1 protein was demonstrable only in zone 3 following phenobarbital induction (Figs. 1C and 2C). Very weak reaction of CYP2B1/2 proteins and no detectable CYP3A1 protein was observed in the nonphenobarbital treated control groups. These observations indicate that the ability of hepatocytes to respond to phenobarbital induction of these P450 proteins is determined, at least in part, by the acinar zone location of the cells within the liver lobule.

**Responsiveness to Phenobarbital Induction and Zonal Origin in Hepatic Hyperplastic Nodules**

Examination of the expression of CYP2B1/2 and 3A1 in preneoplastic lesions induced by the Solt-Farber protocol revealed that some, but not all, of these nodules respond to induction by phenobarbital [Fig. 1C,D; (16)]. In contrast, all of the nodules induced by the AFB administration protocol positively expressed CYP2B1/2 (16) and 3A1 (Fig. 2C-E). CYP2B1/2 proteins were uniformly expressed in all of the AFB-induced nodules, although small focal areas of negatively stained hepatocytes could be seen in some of the nodules. In contrast, a wide spectrum of staining patterns for CYP2B1/2, from completely negative staining (similar to that in the periportal area) to highly positive staining (similar to that of the centrilobule area), was observed in the nodules induced by the Solt-Farber resistance protocol. CYP3A1 protein was demonstrable in all of the AFB-induced nodules, with
Figure 2. Expression of GGT, GST-P, CYP2B1/2, and 3A1 in hepatic hyperplastic nodules induced by the aflatoxin B1 administration protocol in semi-serial sections (16) (12.5×) (E) enlargement of the boxed area indicated in D (225×).

many small areas of darkly stained cells dispersed among the majority of negatively stained cells, yielding a staining pattern mimicking that of the surrounding tissue. CYP3A1 was expressed only in a small fraction of the nodules in the Solt-Farber resistance group; the majority of nodules had no expression at all.

Single large or smaller repeated doses of AFB typically result in periportal necrosis in rat liver (22–24). We also observed extensive periportal necrosis in the livers of rats given the AFB protocol. The dose level of AFB used in our experiments (10 doses of 150 μg/kg each in two successive weeks, IP) was considerably lower than that used by other investigators to induce liver necrosis (22,23). However, using the same dosing regimen, we observed a marked difference in toxicity between animals maintained on a standard rodent chow diet and those maintained on a purified (AIN 76-A) diet. The 150 μg/kg/day dose of AFB produced minimal necrosis and only a few, tiny preneoplastic foci in animals maintained on the chow diet, but resulted in widespread liver necrosis and numerous large nodules in rats maintained on the AIN-76A diet (data not shown).

These data suggest that AFB-nodules produced in our studies might be derived solely from clonal expansion of initiated cells originating in the centrilobular region. Close observation of the distribution of early foci 1 or 2 weeks after the last dose in AFB-treated animals revealed numerous small GST-P-positive hepatocyte foci in the centrilobular region, suggesting that these foci originate from this region. Thus, we suggest that the ability of AFB-induced foci/nodules to respond to phenobarbital induction of CYP2B1/2 and 3A1 may be an inherited characteristic reflecting the zonal origin of the precursor hepatocyte. Similarly, the inconsistent expression of the P450 enzymes among nodules induced by the Solt-Farber resistance protocol might result from the fact that these lesions arise from throughout the lobule, without zonal preference (25,26). This hypothesis is schematically explained in Figure 3.

Messenger RNA levels of six P450s in 10 surgically isolated large nodules (induced by the Solt-Farber resistance protocol and several additional doses of acetaminofluorene) are shown in Table 1. In every instance, the mRNA levels for all P450s examined in individual nodules was greatly decreased relative to normal liver or surrounding tissue. These data are consistent with the hypothesis that both constitutive expression and the responsiveness to induction of specific P450s is determined, at least in part, by the zonal origin of the lesions. It is unlikely that the decrease in expression of six different P450 genes resulted from specific “damage” to all 6 genes in all 10 nodules. Similarly, it is unlikely that all the nodules produced by the AFB protocol had damage in all three genes of CYP2B1, 2B2, and 3A1. Roomi and colleagues (27) suggested that the uniform underexpression of numerous P450 enzymes in preneoplastic lesions was not a result of alterations in the structural genes or regulatory ele-
Table 1. Slot-blot measurement of mRNA of CYP1A2, 2B1, 2B2, 3A1, 2C6, and 2C11 in rat hepatic hyperplastic nodules (HHN) induced by dimethylnitrosamine and repeated doses of acetylaminofluorene with or without phenobarbital treatment.*

| Samples                     | 1A2 | 2B1 | 2B2 | 2C6 | 2C11 | 3A1 |
|-----------------------------|-----|-----|-----|-----|------|-----|
| Phenobarbital group         |     |     |     |     |      |     |
| Control                     | 1.00| 1.00| 1.00| 1.00| 1.00 | 1.00|
| Surrounding tissue          | 0.62| 0.72| 0.62| 0.71| 0.58 | 0.66|
| HHN 1                       | 0.33| 0.22| 0.31| 0.34| 0.08 | 0.08|
| HHN 2                       | 0.50| 0.21| 0.30| 0.33| 0.06 | 0.12|
| HHN 3                       | 0.25| 0.09| 0.13| 0.17| 0.05 | 0.07|
| HHN 4                       | 0.24| 0.15| 0.17| 0.60| 0.18 | 0.16|
| HHN 5                       | 0.35| 0.23| 0.31| 0.40| 0.06 | 0.10|
| Nonphenobarbital group      |     |     |     |     |      |     |
| Control                     | 1.48| 0.00| 0.04| 0.17| 0.56 | 0.15|
| Control surrounding tissue  | 0.93| 0.00| 0.06| 0.15| 0.42 | 0.11|
| HHN 1                       | 0.32| 0.00| 0.04| 0.00| 0.03 | 0.02|
| HHN 2                       | 0.45| 0.00| 0.03| 0.00| 0.04 | 0.08|
| HHN 3                       | 0.27| 0.00| 0.03| 0.14| 0.04 | 0.08|
| HHN 4                       | 0.40| 0.00| 0.04| 0.07| 0.04 | 0.08|
| HHN 5                       | 0.40| 0.00| 0.05| 0.26| 0.03 | 0.12|

*Data are expressed as the ratio of mRNA from phenobarbital-treated control liver, which is set as 1.00.

*Control animals given acetylaminofluorene and partial hepatectomy but no diethylnitrosamine, such that no HHN were formed.
stances such as steroid hormones, eicosanoid hormones, and phenobarbital, which are modulators of DNA and RNA synthesis (17).

The mechanisms of induction and regulation of CYP2B1/2 and 3A1 in hepatocytes remains poorly understood, and the influence of the cell environment on P450 expression remains uncertain. It does appear that the "genotype" of a nodule, which is presumably monoclonal in origin, does not fully determine the expression of P450s. For example, although some AFB1-induced nodules are uniformly stained for CYP2B1/2, patches of negatively stained hepatocytes can be seen in other nodules, irrespective of their monoclonal origin. This is most evident for induction of CYP3A1 in AFB1-induced nodules, where marked heterogeneity in induction/expression of this P450 was evident in all nodules. More studies are required to answer these questions and to test this hypothesis further.

REFERENCES

1. Okita, K., Noda, K., Fukumoto, Y., and Takemoto, T. Cytochrome P-450 in hyperplastic liver nodules during hepatocarcinogenesis with N-2-fluorenylacetic acid in rats. Jpn. J. Cancer Res. 67: 899-902 (1976).

2. Cameron, R., Sweeney, G., Jones, K., Lee, G., and Farber, E. A relative deficiency of cytochrome P-450 and aryl hydrocarbon [benz(a)pyrene] hydroxylase in hyperplastic nodules induced by 2-acetylaminofluorene in rat liver. Cancer Res. 36: 3888-3893 (1976).

3. Roomi, M. W., Ho, R. K. Sharma, B. S. R., and Farber, E. A common biochemical pattern in preneoplastic hepatic nodules generated in four different models in the rat. Cancer Res. 45: 554-571 (1985).

4. Farber, E. Cellular biochemistry of the stepwise development of cancer with chemicals: G.H.A. Clowes Memorial lecture. Cancer Res. 44: 5463-5474 (1984).

5. Farber, E. The biochemistry of preneoplastic liver: a common metabolic pattern in hepatocyte nodules. Can. J. Biochem. Cell Biol. 62: 486-494 (1984).

6. Diwan, B. A., Rice, J. M., Nims, R. W., Lubet, R. A., Hu, H., and Ward, J. M. P-450 enzyme induction of 5-ethyl-5-phenylhydantoin and 5,5-dihydrithyldantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethyliamine in rats. Cancer Res. 48: 2492-2497 (1988).

7. Lubet, R. A., Nims, R. W., Ward, J. M., Rice, J. M., and Diwan, B. A. Induction of cytochrome P450b and its relationship to liver tumor promotion. J. Am. Coll. Toxicol. 8: 259-268 (1989).

8. Peraino, C., Fry, R. J., Staffeld, E., and Christopher, J. P. Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydantoin, and dichlorodiphenyl-trichloroethane on 2-fluorenylacetic acid-induced hepatic tumorigenesis in the rat. Cancer Res. 35: 2884-2890 (1975).

9. Schulte-Hermann, R. Tumor promotion in the liver. Arch. Toxicol. 57: 147-158 (1985).

10. Wolff, G. L., Leakey, J. E. A., Bazare, J. J., Harmon, J. R., Webb, P. J., and Law, M. G. Susceptibility to phenobarbital promotion of hepatotumorigenesis: correlation with differential expression and induction of hepatic drug metabolizing enzymes in heavy and light male (C3H x C57) F1 hybrid mice. Carcinogenesis 12: 911-915 (1991).

11. Schulte-Hermann, R., and Timmermann-Trosiener, I. Aberrant expression of adaptation to phenobarbital may cause selective growth of foci of altered cells in rat liver. In: Models, Mecha-
nisms and Etiology of Tumor Promotion (M. Borzsonyi and K. Lapis et al., Eds.), IRC Scientific Publication No. 56, Lyon, 1984, pp. 67-75.

12. Schulte-Hermann, R., Timmermann-Trosiener, I., and Schuppler, J. Facilitated expression of adaptive responses to phenobarbital in putative pre-stages of liver cancer. Carcinogenesis 7: 1651-1655 (1986).

13. Buchmann, A., Schwarz, M., Schmitt, R., Wolf, C. R., Oesch, F., and Kunz, W. Development of cytochrome P-450-altered preneoplastic and neoplastic lesions during nitrosamine-induced hepa
tocarcinogenesis in the rat. Cancer Res. 47: 2911-2918 (1987).

14. Tsuda, H., Moore, M. A., Asamoto, M., Inoue, T., Ito, N., Satoh, K., Ichihara, A., Nakamura, T., Amelizad, Z., and Oesch, F. Effect of modifying agents on the phenotypic expression of cytochrome P-450, glutathione S-transferase molecular forms, microsomal epoxide hydrolase, glucose-6-phosphate dehydrogenase and y-glutamyltranspeptidase in rat liver preneoplastic lesions. Carcinogenesis 9: 547-554 (1988).

15. Asamoto, M., Tsuda, H., Kato, T., Ito, N., Masuko, T., Hashimoto, Y., and Nagase, S. Strain differences in susceptibility to 2-acetylaminofluorene and phenobarbital promotion of hepatocarcinogenesis: immunohistochemical analysis of cytochrome P-450 isozyme induction by 2-acetylaminofluorene and phenobarbital. Jpn. J. Cancer Res. 80: 1041-1046 (1989).

16. Chen, Z.-Y., and Eaton, D. L. Differential regulation of cytochrome P450 2B1/2 by phenobarbital in hepatic hyperplastic and neoplastic nodules induced by aflatoxin B1 or diethylstilbestrol plus 2-acetylaminofluorene in male F344 rats. Toxicol. Appl. Pharmacol. 111: 132-144 (1991).

17. Chen, Z.-Y., and Eaton, L. D. Association between growth stimulation by phenobarbital and expression of cytochromes P450 1A1, 1A2, 2B1/2 and 3A1 in hepatic hyperplastic nodules in male F344 rats. Carcinogenesis, 13: 675-682 (1992).

18. Semple-Hobert, E., Hays, A., Armstrong, D., Becker, R. A., Race, W. L., and Farber, E. Alternative methods of selecting rat hepatic carcinomas resistant to 2-acetylaminofluorene. Int. J. Cancer 40: 643-645 (1987).

19. Omiecinski, C. J., Waiz, F. G. J., and Vlasuk, G. K. Phenobarbital induction of rat liver cytochrome P-450b and P-450c. J. Biol. Chem. 260: 3247-3250 (1985).

20. Wojcik, E., Dvorak, C., Chiamale, J., Traber, P. G., Keren, D., and Gumucio, J. J. Demonstration by in situ hybridization of the zonal modulation of rat liver cytochrome P-450b and P-450c gene expression after phenobarbital. J. Clin. Invest. 82: 658-666 (1988).

21. Schwarz, M., Peres, G., Buchmann, A., Friedberg, R., Waxman, D. J., and Kunz, W. Phenobarbital induction of cytochrome P-450 in normal and preneoplastic rat liver: comparison of enzyme and mRNA expression as detected by immunohistochemistry and in situ hybridization. Carcinogenesis 8: 1355-1357 (1987).

22. Newberne, P. M., and Butler, W. H. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. Cancer Res. 29: 230-250 (1969).

23. Butler, W. H. Acute toxicity of aflatoxin B1 in rats. Br. J. Cancer 18: 764-762 (1964).

24. Liu, Y. L., Roeuck, B. D., Yager, J. D., Groopman, J. D., and Kensler, T. W. Protection by 5-(2-pyrazinyl)-1-methyl-1,2- thiophene-3-thiante (OTipraz) against the hepatotoxicity of aflatoxin B1 in the rat. Toxicol. Appl. Pharmacol. 83: 442-451 (1988).

25. Solt, D. B., Medline, A., and Farber, E. Rapid emergence of carcino-gen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am. J. Pathol. 88: 595-618 (1977).

26. Cameron, R. G. Identification of putative first cellular step of chemical hypotocarcinogenesis. Cancer Lett. 47: 163-167 (1989).

27. Rushmore, T. H., Sharma, R. N. S., and Roomi, M. W. Identification of a characteristic cytokine polypeptide of rat preneoplastic hepatic phenotype nodules as placental glutathione S-transferase. Biochem. Biophys. Res. Commun. 143: 98-106 (1987).

28. Gebhardt, R., Tanaka, R., and Williams, G. M. Glutamine synthetase heterogeneous expression as a marker for the cellular lineage of preneoplastic and neoplastic liver populations. Carcinogenesis 10: 1917-1923 (1989).
29. Zajicek, G., Oren, R., and Weinreb, M. J. The streaming liver. Liver 5: 293–300 (1985).
30. Arber, N., Zajicek, G., and Ariel, I. The streaming liver II: hepatocyte life history. Liver 8: 80–87 (1988).

31. Rappaport, A. M. The acinus-microvascular unit of the liver. New York, Raven Press, 1981, pp. 175–192.
32. Jungermann, K., and Katz, N. Functional specialization of different hepatocyte populations. Physiol. Rev. 69: 708–764 (1989).